Longitudinal Metabolomic and Epigenetic Profiling of Bodyfluids From Patients With Lung and Brain Cancer Receiving Radiation Therapy
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer, Other Indications, Brain Cancer |
| Therapuetic Areas: | Oncology, Other |
| Healthy: | No |
| Age Range: | 19 - Any |
| Updated: | 4/14/2017 |
| Start Date: | October 4, 2012 |
| End Date: | December 30, 2017 |
| Contact: | The Ohio State University Comprehensive Cancer Center |
| Email: | Jamesline@osumc.edu |
| Phone: | 1-800-293-5066 |
Biomarker Discovery for Toxicity and Survival in Radiation Oncology: An Integrative Molecular-Clinical Approach
This research trial studies metabolomic and other molecular profiling to identify predictive
biomarkers for radiation toxicity and survival in patients with lung or brain cancers
receiving radiation therapy. Studying samples of blood, urine, and tissue from patients with
lung or brain cancer in the laboratory may help doctors identify and learn more about
biomarkers related to cancer and predict which patients are at higher risk for developing
radiation side effects and how well patients will respond to radiation treatment.
biomarkers for radiation toxicity and survival in patients with lung or brain cancers
receiving radiation therapy. Studying samples of blood, urine, and tissue from patients with
lung or brain cancer in the laboratory may help doctors identify and learn more about
biomarkers related to cancer and predict which patients are at higher risk for developing
radiation side effects and how well patients will respond to radiation treatment.
PRIMARY OBJECTIVES:
I. Metabolomic and epigenetic urine and blood profiles of patients undergoing radiation
therapy for lung cancer associated with the development of radiation pneumonitis.
II. Metabolomic and epigenetic urine and blood profiles of patients undergoing radiation
therapy for brain cancer associated with the development of radiation necrosis.
SECONDARY OBJECTIVES:
I. Metabolomic and epigenetic urine, blood, and tissue profiles of patients undergoing
radiation therapy for lung and brain cancer associated with survival.
OUTLINE:
Collected blood, urine, and tissue samples are analyzed for biomarkers via metabolomic and
epigenetic profiling using massspectrometry, array, and sequencing-based technology.
I. Metabolomic and epigenetic urine and blood profiles of patients undergoing radiation
therapy for lung cancer associated with the development of radiation pneumonitis.
II. Metabolomic and epigenetic urine and blood profiles of patients undergoing radiation
therapy for brain cancer associated with the development of radiation necrosis.
SECONDARY OBJECTIVES:
I. Metabolomic and epigenetic urine, blood, and tissue profiles of patients undergoing
radiation therapy for lung and brain cancer associated with survival.
OUTLINE:
Collected blood, urine, and tissue samples are analyzed for biomarkers via metabolomic and
epigenetic profiling using massspectrometry, array, and sequencing-based technology.
Inclusion Criteria:
- Consultation with the Radiation Oncology department of the Ohio State University
(OSU) Comprehensive Cancer Center
- The following diagnoses will be included: malignant neoplasm of the brain; primary
malignant neoplasm of trachea bronchus and lung; primary malignant neoplasm of the
cervix uteri and primary malignant neoplasm the prostate
Exclusion Criteria:
- Being an inmate
We found this trial at
1
site
300 W 10th Ave
Columbus, Ohio 43210
Columbus, Ohio 43210
(800) 293-5066
Principal Investigator: Arnab Chakravarti, MD
Phone: 614-293-8415
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center...
Click here to add this to my saved trials
